磨玻璃成分对螺旋断层放疗立体定向放疗早期肺癌预后的影响
研究纳入2013年1月至2022年12月接受立体定向放疗的239例早期肺癌患者,按磨玻璃成分分为亚实性组65例与实性组174例。亚实性组总生存和进展后生存优于实性组,局部区域复发率更低,磨玻璃成分是独立预后因素。
要点
- 亚实性组3年、5年、9年肺癌特异性生存率分别为94.7%、90.9%、82.7%,均高于实性组。
- 亚实性组中位无进展生存72.5个月,实性组50.5个月(p=0.030)。
- 亚实性组局部区域复发率10.4%,低于实性组的25.9%(p=0.035)。
核心结论
- 病灶存在磨玻璃成分是肺癌特异性生存和无进展生存的独立预后因素。
- 接受立体定向放疗的亚实性结节预后更好,局部区域复发率显著更低。
- 作者认为应将磨玻璃成分作为立体定向放疗患者风险分层的实用指标以指导治疗决策。
研究设计与样本
- 研究纳入2013年1月至2022年12月接受立体定向放疗的239例早期肺癌患者(T1-2N0M0)。
- 按磨玻璃成分将患者分为亚实性组65例(实性成分占比0.25至1)和实性组174例(实性成分占比为1)。
- 采用Cox回归模型进行单因素和多因素分析,并使用稳定化逆概率治疗加权调整混杂因素。
- 复发率采用竞争风险分析并通过Gray检验比较。
主要发现
- 多因素分析中,女性、外周位置和亚实性结节是肺癌特异性生存的有利预后因素。
- 多因素分析中,外周位置、亚实性结节和辅助治疗是无进展生存的有利预后因素。
- 亚实性组与实性组中位肺癌特异性生存均未达到(p=0.003),3年、5年、9年生存率分别为94.7%对80.3%、90.9%对64.1%、82.7%对53.5%。
- 亚实性组与实性组中位无进展生存分别为72.5个月和50.5个月(p=0.030),3年、5年、9年无进展生存率分别为75.4%对61.2%、56.6%对44.9%、48.6%对23.3%。
- 稳定化逆概率治疗加权后(n=240),亚实性组与实性组中位肺癌特异性生存均未达到(p=0.024),3年、5年、9年生存率分别为94.0%对82.4%、92.2%对67.7%、85.3%对58.2%。
临床怎么用
- 作者认为应将磨玻璃成分作为立体定向放疗患者风险分层的实用指标以指导治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to investigate the prognostic impact of ground-glass opacity (GGO)-component in early-stage lung cancer patients treated with stereotactic body radiotherapy (SBRT). METHODS: From January 2013 to December 2022, 239 early-stage lung cancer patients (T1-2N0M0) underwent SBRT. They were categorized into two groups based on the presence of GGO-component: 65 patients in the subsolid group with a consolidation tumor ratio (CTR) between 0.25 and 1 and 174 patients in the solid group with a CTR of 1. Lung cancer-specific survival (LCSS) and progression-free survival (PFS) were analyzed using Cox regression models for both univariate and multivariate analyses to identify prognostic factors. Stabilized inverse probability of treatment weighting (IPTW) was employed for adjusting confounding factors. Recurrence incidence was assessed using competing risk analysis and compared using Gray's test. RESULTS: In the multivariate analysis, female, peripheral location, and subsolid nodules were favorable prognostic factors for LCSS; peripheral location, subsolid nodules, and adjuvant therapy were favorable prognostic factors for PFS. Between the subsolid (n = 65) and solid groups (n = 174), the median LCSS were not reached (p = 0.003), with 3-, 5-, and 9-year LCSS rates of 94.7% versus 80.3%, 90.9% versus 64.1%, 82.7% versus 53.5%, respectively. The median PFS were 72.5 months and 50.5 months (p = 0.030), with 3-, 5-, and 9-year PFS rates of 75.4% versus 61.2%, 56.6% versus 44.9%, 48.6% versus 23.3%, respectively. After stabilized IPTW (n = 240), the median LCSS were not reached (p = 0.024), with 3-, 5-, and 9-year LCSS rates of 94.0% versus 82.4%, 92.2% versus 67.7%, 85.3% versus 58.2%, respectively. The median PFS were 60.2 months and 50.5 months (p = 0.096), with 3-, 5-, and 9-year PFS rates of 73.8% versus 61.0%, 53.5% versus 46.2%, 46.8% versus 22.4%, respectively. The subsolid group had lower rates of locoregional recurrence (LRR) (10.4% vs. 25.9%, p = 0.035) and distant metastasis (DM) (17.1% vs. 37.9%, p = 0.064) compared to the solid group. CONCLUSIONS: The presence of GGO-component in the lesion is an independent prognostic factor for LCSS and PFS. Subsolid nodules treated with SBRT demonstrated better prognosis, with significantly lower rates of local-regional recurrence. We should highlight GGO-component as a practical indicator for risk stratification of SBRT patients to guide treatment decisions.
引用
- Ma J, Fan S, Huang W, et al. Impact of ground-glass component on prognosis in early-stage lung cancer treated with stereotactic body radiotherapy via Helical Tomotherapy. Radiat Oncol. 2024. PMID: 39696596. doi:10.1186/s13014-024-02571-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。